|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Lewy Body Disease
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
14-3-3 protein sigma isoform co-localizes with phosphorylated α-synuclein in Lewy bodies and Lewy neurites in patients with Lewy body disease.
|
29555518 |
2018 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Dementia with Lewy bodies (DLB) and Parkinson's Disease (PD) are neurodegenerative disorders of the aging population characterized by the abnormal accumulation of alpha-synuclein (alpha-syn).
|
21103359 |
2010 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Lewy body dementia is the second most common neurodegenerative dementia and is pathologically characterized by α-synuclein positive cytoplasmic inclusions, with varying amounts of amyloid-β (Aβ) and hyperphosphorylated tau (tau) aggregates in addition to synaptic loss.
|
28269775 |
2017 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Lewy body disease (LBD) is characterized by accumulation of aggregated α-synuclein in the central nervous system as eosinophilic cytoplasmic inclusions called Lewy bodies.
|
29909202 |
2018 |
|
Lewy Body Disease
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.
|
31189032 |
2019 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein protein is present in the pathologic lesions of familial and sporadic PD, and diffuse Lewy body disease, indicating an important pathogenic role for alpha-synuclein.
|
10967135 |
2000 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
alpha-Synuclein has been identified as a component of Lewy bodies in Parkinson's disease and diffuse Lewy body disease, and glial cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA).
|
11279280 |
2001 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease.
|
11708989 |
2001 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein is a major component of Lewy bodies (LBs) in the substantia nigra and cortex in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), and in glial inclusions in multiple systems atrophy (MSA).
|
12498958 |
2003 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
alpha-Synuclein aggregation and toxicity play a major role in Parkinson's disease and dementia with Lewy bodies.
|
15522241 |
2004 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein mutations are much less frequent, but the importance of alpha-synuclein has been confirmed by the demonstration of alpha-synuclein deposition as Lewy bodies in patients with PD and Lewy body dementia.
|
17563248 |
2007 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
alpha-Synuclein (alpha-syn) is the major component of pathologic inclusions that characterize neurodegenerative disorders such as Parkinson disease, dementia with Lewy body disease, and multiple system atrophy.
|
18451726 |
2008 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein (alpha-syn) aggregation is a neuropathological hallmark of many diseases including Dementia with Lewy Bodies (DLB) and Parkinson's Disease (PD), collectively termed the alpha-synucleinopathies.
|
19944097 |
2010 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
|
21863007 |
2011 |
|
Lewy Body Disease
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
α-Synuclein is causative for autosomal dominant familial Parkinson disease and dementia with Lewy bodies, and the phosphorylation of α-synuclein at residue Ser-129 is a key posttranslational modification detected in Parkinson disease/dementia with Lewy bodies lesions.
|
22232559 |
2012 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
α-Synuclein has been reported to be important in modulating brain plasticity and to be a key protein in neurodegenerative diseases, including Lewy body dementia (LBD).
|
23175842 |
2012 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
α-Synuclein aggregation in neurons is a well-characterized feature of Parkinson's disease and dementia with Lewy bodies.
|
24502382 |
2014 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein is a key protein in Parkinson disease (PD) and dementia with Lewy bodies.
|
25383638 |
2014 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alpha-synuclein (αSyn) plays a central role in the pathogenesis of Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
|
26362253 |
2015 |
|
Lewy Body Disease
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Alpha-Synuclein (aSyn) misfolding and aggregation is common in several neurodegenerative diseases, including Parkinson's disease and dementia with Lewy bodies, which are known as synucleinopathies.
|
27123591 |
2016 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
α-Synuclein is the major component of Lewy bodies and Lewy neurites in Parkinson disease and dementia with Lewy bodies and of glial cytoplasmic inclusions in multiple system atrophy.
|
27226637 |
2016 |
|
Lewy Body Disease
|
0.800 |
Biomarker
|
disease |
BEFREE |
α-Synuclein (α-syn) aggregates (Lewy bodies) in Dementia with Lewy Bodies (DLB) may be associated with disturbed calcium homeostasis and oxidative stress.
|
27746320 |
2016 |